Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999

Gaetano Bacci, Alessandra Longhi, Enza Barbieri, Stefano Ferrari, Mario Mercuri, Antonio Briccoli, Michela Versari, Elettra Pignotti, Piero Picci

Research output: Contribution to journalArticle

Abstract

The relative risk of second tumors in patients with Ewing sarcoma is controversial, and little is known about their treatment and outcome. The purpose of the current study was to define the incidence and features of second tumors among 597 long-term survivors of nonmetastatic Ewing sarcoma treated with adjuvant and neoadjuvant chemotherapy, radiotherapy, and/or surgery. The authors found that the risk of secondary malignancy after adjuvant or neoadjuvant treatment of Ewing sarcoma is higher than that after other childhood or adolescent cancers only after radiotherapy. Based on this, postoperative radiotherapy should be avoided when surgery with adequate margins is feasible.

Original languageEnglish
Pages (from-to)517-520
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume27
Issue number10
DOIs
Publication statusPublished - Oct 2005

Keywords

  • Ewing sarcoma
  • Radiotherapy
  • Second tumor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999'. Together they form a unique fingerprint.

  • Cite this